-
-
-
-
-
-
-
LifeSci Capital Downgrades Verve Therapeutics (VERV) to Market Perform
-
-
-
-
-
-
-
Verve Therapeutics (VERV) PT Raised to $24 at Guggenheim
-
-
-
-
-
-
-
Verve Therapeutics (VERV) Announces Positive Initial Data from the Heart-2 Phase 1b Trial of VERVE-102
-
-
-
-
-
-
-
Form SCHEDULE 13G/A Verve Therapeutics, Inc. Filed by: ARK Investment Management LLC
-
-
-
-
-
-
-
Form SC 13G/A Verve Therapeutics, Inc. Filed by: ARK Investment Management LLC
-
408,849 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

